BioRegenx, Inc.
BRGX
$0.0129
$0.001917.27%
| Weiss Ratings | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 16.22% | |||
| 30-Day Total Return | 43.33% | |||
| 60-Day Total Return | -18.87% | |||
| 90-Day Total Return | -27.53% | |||
| Year to Date Total Return | 43.33% | |||
| 1-Year Total Return | -78.96% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -84.82% | |||
| 52-Week Low % Change | 43.73% | |||
| Price | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.09 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Feb 05, 2025 | |||
| 52-Week High Price (Date) | Mar 18, 2024 | |||
| Valuation | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 12.34M | |||
| Enterprise Value | 14.42M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | 22.22% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -16.13 | |||
| Price/Book (Q) | 0.91 | |||
| Enterprise Value/Revenue (TTM) | -17.34 | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -7.07 | |||
| Enterprise Value/EBIT | -3.91 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 956.53M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 866 770 4067 | |||
| Address | 7407 Ziegler Road Chattanooga, TN 37421 | |||
| Website | www.findit.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 443.16% | |||
| Profit Margin | 505.98% | |||
| Management Effectiveness | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -24.93% | |||
| Return on Equity | -- | |||
| Income Statement | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -831.70K | |||
| Total Revenue (TTM) | -831.70K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -675.90K | |||
| EBITDA (TTM) | -2.04M | |||
| EBIT (TTM) | -3.69M | |||
| Net Income (TTM) | -4.21M | |||
| Net Income Avl. to Common (TTM) | -4.21M | |||
| Total Revenue Growth (Q YOY) | -24.98% | |||
| Earnings Growth (Q YOY) | 84.32% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | 90.24% | |||
| Balance Sheet | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 70.10K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 371.00K | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 13.56M | |||
| Current Ratio (Q) | 0.105 | |||
| Book Value Per Share (Q) | $0.01 | |||
| Total Assets (Q) | 17.36M | |||
| Total Current Liabilities (Q) | 3.52M | |||
| Total Debt (Q) | 2.15M | |||
| Total Liabilities (Q) | 3.80M | |||
| Total Common Equity (Q) | 13.56M | |||
| Cash Flow | BRGX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -139.20K | |||
| Cash from Financing (TTM) | -209.10K | |||
| Net Change in Cash (TTM) | 502.80K | |||
| Levered Free Cash Flow (TTM) | 19.96M | |||
| Cash from Operations (TTM) | 851.90K | |||
